GV101 ROCK2 Inhibitor
GV101 is an oral selective ROCK2 inhibitor being developed by Graviton BioScience. ROCK2 is a key regulator of multiple cellular pathways involved in inflammation, fibrosis, metabolism, and gene expression. GV101 was found to increase levels of frataxin.
In August 2026, the U.S. Food and Drug Administration (FDA) cleared an Investigational New Drug (IND) application for GV101 in FA, enabling initiation of a Phase II clinical study.
Stages of Development for GV101
The drug development process can be thought of as a series of stages, and successful drugs must pass through each stage to become available to patients.
Researchers at the University of Massachusetts Chan Medical School conducted studies to identify cellular pathways involved in FXN gene repression and discovered that the kinases ROCK1 and ROCK2 might play a role in regulating frataxin expression.
In laboratory studies, reducing ROCK1 or ROCK2 activity increased FXN messenger RNA (mRNA) and frataxin protein levels in multiple FA cell models. These findings suggested that ROCK inhibition could represent a therapeutic strategy to restore frataxin production in Friedreich’s ataxia.
GV101 is a clinical-stage, selective inhibitor of Rho/Rho-associated coiled-coil containing protein kinase 2 (ROCK2). ROCK2 is a key regulator of multiple cellular pathways involved in inflammation, fibrosis, metabolism, and gene expression. Through inhibition of ROCK2, GV101 has the potential to modulate disease-relevant biological processes, including increasing frataxin production.
In preclinical studies of cell lines derived from FA patients, Graviton has reported that GV101 increased frataxin protein levels, supporting development of the compound as a potential disease-modifying therapy for Friedreich’s ataxia.
Prior to development in FA, GV101 was evaluated in clinical studies in other disease areas. Graviton has reported that more than 500 participants have received GV101, including treatment durations of up to 24 weeks and extension studies lasting more than one year. Across these studies, GV101 demonstrated a favorable safety and tolerability profile.
Graviton also reported that treatment with GV101 increased frataxin levels in peripheral blood mononuclear cells (PBMCs) collected from participants in an obesity study, providing initial clinical evidence that ROCK2 inhibition may increase frataxin expression in humans and supporting further development of GV101 for FA.
In August 2026, Graviton BioScience announced that the FDA had cleared an IND application for a novel capsule formulation of GV101 for the treatment of Friedreich’s ataxia, enabling initiation of a Phase II clinical study in individuals living with FA.
According to Graviton, the Phase II study will evaluate the novel capsule formulation of GV101 that was specifically optimized for development in Friedreich’s ataxia and other orphan indications. The company is developing GV101 as a potential disease-modifying therapy based on its ability to increase frataxin protein levels.